Form 4: Tarsus Director Sells Shares Under 10b5-1 Plan

William J. Link, a director at Tarsus Pharmaceuticals, sold 12,500 shares of common stock on March 16, 2026, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• William J. Link, PHD, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported sales of common stock.
• The transactions occurred on March 16, 2026.
• A total of 12,500 shares of common stock were disposed of in three separate transactions.
• The shares were sold at weighted average prices of $68.09, $69.03, and $69.75.
• These sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Link on September 8, 2025.
• Following these transactions, Mr. Link beneficially owns 116,332 shares of Tarsus Pharmaceuticals, Inc. common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned under a Rule 10b5-1 plan, mitigating concerns typically associated with insider selling.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 trading plan, which indicates the decision to sell was made in advance and not based on recent non-public information, reducing concerns about opportunistic insider selling.

Negatives

• The transactions represent a reduction in direct insider ownership by a director, which can sometimes be perceived negatively by the market as a decrease in management's stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are common for personal financial planning, such as diversification or liquidity, and are generally viewed with less concern than unscheduled sales, as the trading decision is made in advance of any potential material non-public information.

Stakeholder Impact

• Shareholders will observe a reduction in a director's direct ownership, which could be interpreted differently depending on individual investment strategies, though the pre-planned nature of the sale lessens potential negative implications.

Key Dates

Recommendation

The sale by a director, while reducing insider ownership, was executed under a pre-established Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new material information. This event alone does not provide sufficient new information to warrant a change in investment recommendation.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, insider sale, Rule 10b5-1, beneficial ownership, William J. Link